Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8721MR)

This product GTTS-WQ8721MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8721MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9899MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ5508MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ3758MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ10890MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ13364MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ5424MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ15674MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ10181MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LC1004-002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW